Bevacizumab combined with chemotherapy for glioblastoma: a meta-analysis of randomized controlled trials

Shou-Bo Yang, Kai-Di Gao, Tao Jiang, Shu-Jun Cheng and Wen-Bin Li _

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:57337-57344. https://doi.org/10.18632/oncotarget.16924

Metrics: PDF 1914 views  |   HTML 4047 views  |   ?  


Shou-Bo Yang1, Kai-Di Gao2, Tao Jiang3, Shu-Jun Cheng1 and Wen-Bin Li1

1Department of Oncology, Beijing Shijitan Hospital, Capital Medical University, Beijing, China

2Beijing Rehabilitation Hospital of Capital Medical University, Beijing, China

3Department of Neurosurgery, Tiantan Hospital, Capital Medical University, Beijing, China

Correspondence to:

Wen-Bin Li, email: [email protected]

Keywords: bevacizumab, chemotherapy, glioblastoma, meta-analysis, prognosis

Received: October 24, 2016     Accepted: March 22, 2017     Published: April 07, 2017


Bevacizumab, as antibodies, were applied to inhibit tumor angiogenesis by preventing activation of vascular endothelial growth factor receptor. We analyzed four clinical trials, including 607 patients, to investigate the efficacy and safety of bevacizumab when combined with chemotherapy for the treatment of glioblastomas. Results demonstrated that bevacizumab when combined with chemotherapy improved progression-free survival (HR = 0.66; 95% CI 0.56–0.78; p < 0.00001) compared with bevacizumab or chemotherapy alone. Furthermore, overall survival showed insignificant difference between two arms (HR 0.99; 95% CI 0.8–1.21; p = 0.92). However, we found that patients treated with bevacizumab-containing therapy reported increased objective response rate (OR 1.85, 95% CI 1.17–2.93; p = 0.009), but more treatment-related adverse events (OR 1.75; 95% CI 1.09–2.83; p = 0.02).

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 16924